Presenting clinical, laboratory, and pathological features of the 66 patients with SMZL
| Characteristic . | Value . |
|---|---|
| Clinical features, n (%) | |
| Sex (N = 66) | |
| Male | 28 (42.4) |
| Female | 38 (57.6) |
| IIL score (N = 66) | |
| Low risk | 27 (40.9) |
| Intermediate risk | 19 (28.8) |
| High risk | 20 (30.3) |
| Splenectomy (N = 59) | |
| Yes | 18 (30.5) |
| No | 41 (69.5) |
| Disease progression (N = 66) | |
| Yes | 38 (57.6) |
| No | 28 (42.4) |
| Treatment approach at diagnosis (N = 66) | |
| Watchful waiting | 26 (39.4) |
| Other treatment (splenectomy and/or chemotherapy) | 40 (60.6) |
| Type of treatment at diagnosis (N = 40) | |
| CHOP-like regimen (without rituximab) | 8 (20) |
| CHOP-like regimen (with rituximab) | 9 (22.5) |
| Alkylating agents | 2 (5) |
| Purine analogues | 10 (25) |
| Splenectomy | 11 (27.5) |
| Laboratory features (N = 66), mean (range) | |
| Hemoglobin (g/dL) | 11.85 (7-17) |
| White blood cell count, ×109/L | 15.4 (1.8-91) |
| Lymphocytes count, ×109/L | 11.3 (0.3-77.3) |
| Platelets count, ×109/L | 151.8 (51.2-380) |
| LDH, UI/L | 472 (186-1482) |
| Albumin, g/dL | 3.8 (2.9-5.1) |
| Pathological features (N = 66) | |
| Percentage of lymphoid infiltration, % (range) | 35 (5-80) |
| Residual BM hemopoietic cellularity, % (range) | 59 (30-90) |
| Pattern of BM infiltration (N = 66), n (%) | |
| Nodular | 6 (9.1) |
| Interstitial | 9 (13.6) |
| Intrasinusoidal | 6 (9.1) |
| Mixed (nodular ± interstitial ± intrasinusoidal) | 45 (68.2) |
| CD10+ ARC meshwork* (N = 35) | |
| Low | 23 (65.7) |
| High | 12 (34.3) |
| CD31+ microvessel density† (N = 35) | |
| Low | 18 (51.4) |
| High | 17 (48.6) |
| CD40+ SC meshwork* (N = 66) | |
| Low | 43 (65.2) |
| High | 23 (34.8) |
| Characteristic . | Value . |
|---|---|
| Clinical features, n (%) | |
| Sex (N = 66) | |
| Male | 28 (42.4) |
| Female | 38 (57.6) |
| IIL score (N = 66) | |
| Low risk | 27 (40.9) |
| Intermediate risk | 19 (28.8) |
| High risk | 20 (30.3) |
| Splenectomy (N = 59) | |
| Yes | 18 (30.5) |
| No | 41 (69.5) |
| Disease progression (N = 66) | |
| Yes | 38 (57.6) |
| No | 28 (42.4) |
| Treatment approach at diagnosis (N = 66) | |
| Watchful waiting | 26 (39.4) |
| Other treatment (splenectomy and/or chemotherapy) | 40 (60.6) |
| Type of treatment at diagnosis (N = 40) | |
| CHOP-like regimen (without rituximab) | 8 (20) |
| CHOP-like regimen (with rituximab) | 9 (22.5) |
| Alkylating agents | 2 (5) |
| Purine analogues | 10 (25) |
| Splenectomy | 11 (27.5) |
| Laboratory features (N = 66), mean (range) | |
| Hemoglobin (g/dL) | 11.85 (7-17) |
| White blood cell count, ×109/L | 15.4 (1.8-91) |
| Lymphocytes count, ×109/L | 11.3 (0.3-77.3) |
| Platelets count, ×109/L | 151.8 (51.2-380) |
| LDH, UI/L | 472 (186-1482) |
| Albumin, g/dL | 3.8 (2.9-5.1) |
| Pathological features (N = 66) | |
| Percentage of lymphoid infiltration, % (range) | 35 (5-80) |
| Residual BM hemopoietic cellularity, % (range) | 59 (30-90) |
| Pattern of BM infiltration (N = 66), n (%) | |
| Nodular | 6 (9.1) |
| Interstitial | 9 (13.6) |
| Intrasinusoidal | 6 (9.1) |
| Mixed (nodular ± interstitial ± intrasinusoidal) | 45 (68.2) |
| CD10+ ARC meshwork* (N = 35) | |
| Low | 23 (65.7) |
| High | 12 (34.3) |
| CD31+ microvessel density† (N = 35) | |
| Low | 18 (51.4) |
| High | 17 (48.6) |
| CD40+ SC meshwork* (N = 66) | |
| Low | 43 (65.2) |
| High | 23 (34.8) |
Mean age at diagnosis (N=66) was 65 years (range, 35-84 years).
CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone.
Semi-quantitative analysis: low are considered cases with score 0 to 1, and high are cases with a score of 2 to 3.
Low are considered cases with amount of CD31+ vessels below the median value, and high are cases with an amount of CD31+ vessels above the median value.